Inhibikase Therapeutics (IKT) Other Working Capital Changes (2020 - 2025)
Inhibikase Therapeutics (IKT) reported Other Working Capital Changes of $352442.0 for Q4 2025, down 42.83% year-over-year from $616523.0 in Q4 2024, and up 206.83% quarter-over-quarter from -$329894.0 in Q3 2025.
Inhibikase Therapeutics (IKT) Other Working Capital Changes (2020 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has 6 years of Other Working Capital Changes data on file, last reported at $352442.0 in Q4 2025.
- Other Working Capital Changes for Q4 2025 came in at $352442.0, down 42.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $95121.0 (down 83.76% YoY), and the FY2025 annual result was $63319.0, up 397.13% from the prior year.
- Other Working Capital Changes rose to $352442.0 in Q4 2025 per IKT's latest filing, from -$329894.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $3.8 million in Q4 2021 and troughed at -$2.0 million in Q2 2021.
- A 5-year average of $117093.6 and a median of -$61448.0 in 2024 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2021 and 2024: Other Working Capital Changes tumbled 6491.55% in 2021, then soared 503.75% in 2024.
- A 5-year view of Other Working Capital Changes shows it stood at $3.8 million in 2021, then tumbled by 73.32% to $1.0 million in 2022, then tumbled by 115.17% to -$152699.0 in 2023, then soared by 503.75% to $616523.0 in 2024, then tumbled by 42.83% to $352442.0 in 2025.
- Business Quant data shows IKT's Other Working Capital Changes at $352442.0 in Q4 2025, -$329894.0 in Q3 2025, and $72573.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 352,442.00 |
| Dec 31, 2025 | 352,442.00 |
| Sep 30, 2025 | -329,894.00 |
| Sep 30, 2025 | -329,894.00 |
| Jun 30, 2025 | 72,573.00 |
| Jun 30, 2025 | 72,573.00 |
| Dec 31, 2024 | 616,523.00 |
| Dec 31, 2024 | 616,523.00 |
| Sep 30, 2024 | 30,719.00 |
| Sep 30, 2024 | 30,719.00 |
| Jun 30, 2024 | -61,448.00 |
| Jun 30, 2024 | -61,448.00 |
| Mar 31, 2024 | 30,729.00 |
| Mar 31, 2024 | 30,729.00 |
| Dec 31, 2023 | -152,699.00 |
| Dec 31, 2023 | -152,699.00 |
| Sep 30, 2023 | -172,385.00 |
| Sep 30, 2023 | -172,385.00 |
| Jun 30, 2023 | -378,841.00 |
| Jun 30, 2023 | -378,841.00 |